Company Filing History:
Years Active: 2023-2025
Title: Innovations of Shenglong Zhu in Metabolic Disease Treatment
Introduction
Shenglong Zhu is a prominent inventor based in Wuxi, China. He has made significant contributions to the field of medicine, particularly in the treatment of metabolic diseases. With a total of four patents to his name, Zhu's work focuses on innovative therapeutic agents that address critical health issues.
Latest Patents
One of Shenglong Zhu's latest patents is a fusion protein that includes GIP and FGF21, along with its compositions. This invention provides a novel approach for treating metabolic diseases. The fusion protein is designed to treat conditions associated with hyperglycemia and hyperlipidemia, including diabetes, obesity, steatohepatitis, and cardiovascular diseases. The general formula of the fusion protein is R1-L-R2 or R2-L-R1, where R1 represents FGF21 protein or its analogs, R2 denotes GIP or its mutants, and L is a linker peptide. Another significant patent involves an FGF analog aimed at combating metabolic disorders. This FGF19 analog is derived from an FGF19 mutant and is utilized in treating liver impairment, obesity, and diabetes without the side effects commonly associated with such treatments.
Career Highlights
Shenglong Zhu is affiliated with Jiangnan University, where he conducts research and develops innovative solutions for metabolic disorders. His work has garnered attention for its potential to improve health outcomes for individuals suffering from various metabolic conditions.
Collaborations
Zhu collaborates with notable colleagues, including Yongquan Chen and Zhen Wang, to advance research in the field of metabolic disease treatment. Their combined expertise contributes to the development of effective therapeutic strategies.
Conclusion
Shenglong Zhu's innovative work in the field of metabolic disease treatment showcases his commitment to improving health through scientific advancements. His patents reflect a deep understanding of the complexities of metabolic disorders and offer promising solutions for patients worldwide.